Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic strategies for prostate cancer.

A J Armstrong1, P G Febbo, D J George

  • 1Duke Prostate Center, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA. andrew.armstrong@duke.edu

Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology
|April 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

European journal of cancer (Oxford, England : 1990)·2021
Same author

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Systemic therapies beyond hormonal therapy are crucial for advanced prostate cancer. Research is evaluating chemotherapy and other agents in early and late disease stages to improve cure rates.

Area of Science:

  • Urologic Oncology
  • Medical Oncology

Background:

  • Hormonal therapy is standard for advanced prostate cancer.
  • Systemic therapies including chemotherapy are gaining acceptance for hormone-refractory disease.

Purpose of the Study:

  • To review the state of systemic therapy for advanced prostate cancer in 2007.
  • To emphasize agents in phase II and III trials impacting the standard of care.

Main Methods:

  • Review of current systemic therapies for advanced prostate cancer.
  • Emphasis on neoadjuvant, adjuvant, and metastatic settings.
  • Focus on agents in ongoing phase II and III clinical trials.

Main Results:

  • Chemotherapy acceptance is increasing for hormone-refractory prostate cancer.

Related Experiment Videos

  • Ongoing trials aim to define the role of systemic therapy in earlier disease states.
  • Biomarker identification is crucial for predicting treatment sensitivity.

    • Conclusions:

    • Systemic therapies beyond hormonal therapy hold promise for advanced prostate cancer.
    • Clinical trials are essential for advancing prostate cancer management.
    • Personalized treatment approaches based on biomarkers are anticipated.